2023-07-27 10:37:00 ET
- Celularity ( NASDAQ: CELU ) on Thursday announced an ~$3M registered direct offering of class A shares and warrants.
- Shares +7.9% in morning trade.
- The firm inked a deal with a healthcare-focused institutional investor for the purchase and sale of ~8.6M class A shares and warrants to buy up to ~8.6M shares at a combined purchase price of $0.35 per share/warrant.
- The warrants will be exercisable starting six months after the date of issuance and will expire five years following the initial exercise date.
- Celularity ( CELU ) also said certain existing warrants to buy up to 8.9M shares at an exercise price of $0.75 per share and a termination date of October 10, 2028 will be amended once the offering closes.
- The amended warrants will have a reduced exercise price of $0.45 per share.
- The closing of the offering and sale of securities is expected on or about July 31.
- Celularity ( CELU ) also inked an exclusive U.S. commercialization deal with Verséa Ophthalmics, which will distribute Celularity's BIOVANCE and BIOVANCE 3L Ocular products.
For further details see:
Celularity announces $3M registered direct offering, stock up 8%